Alpha Buying: Follow the Money From NVIDIA and Merck
Key takeaways
- Big-name corporate investors are betting on the next wave of AI infrastructure and biotech innovation, but the real upside depends on how well the partnerships translate into commercial traction.
- NVIDIA invested $2 billion in Coherent
- Coherent issued 7.8 million shares at $256.80 each
- NVIDIA owns >47 million CoreWeave shares (June 30)
What happened
NVIDIA and Merck have each taken sizable stakes in five smaller companies—NVIDIA in Coherent (COHR) and CoreWeave, Merck in Alector (ALEC), Entrada Therapeutics, and Eikon Therapeutics. NVIDIA’s $2 billion investment in Coherent came with a multiyear strategic agreement and purchase commitments, while Merck’s holdings total roughly 3.5 million shares in Alector, 1.7 million in Entrada, and 1.7 million in Eikon. The article highlights how these corporate owners signal confidence in the…
Why it matters
Corporate ownership by industry leaders can validate a company’s technology, secure future customer or supplier relationships, and provide capital or expertise that might otherwise be hard to obtain. NVIDIA’s stake in Coherent and CoreWeave suggests a strategic push into AI infrastructure, while Merck’s investments…
Short-term and longer-term
Short-term. NVIDIA’s ownership of Coherent and CoreWeave signals a potential upside if AI data‑center demand continues to grow, especially as NVIDIA supplies chips to CoreWeave.
Longer-term. Over the next 12–18 months, the key question is whether the corporate partnerships will materialize into commercial contracts or accelerated product development.